Richard Scranton MD MPH’s Post

2023 has continued to be a big M&A year for biotech. Congratulations to our portfolio company Reata Pharmaceuticals, Inc. on their acquisition to Biogen for $7.3B. They developed and received approval for their drug Skyclarys, which has a meaningful impact on patients suffering from Friedrich's Ataxia. Lessons from Reata: 1) Success is never linear! Very rarely is a company's first drug the eventual winner. 2) Make sure you are well financed until you can reach that eventual success, which in this case was the company's next drug. 3) Focus on major unmet medical needs. Friedrichs Ataxia is a severe disease with no other medical therapies. https://lnkd.in/em2Pa3gD

𝐀𝐛𝐛𝐕𝐢𝐞 𝐭𝐨 𝐀𝐜𝐪𝐮𝐢𝐫𝐞 𝐋𝐚𝐧𝐝𝐨𝐬 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚, 𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐀𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 AbbVie (NYSE: ABBV) AbbVie and Landos Biopharma, Inc. (NASDAQ: LABP) Landos Biopharma, Inc. announced a definitive agreement where AbbVie will acquire Landos, a clinical-stage biopharmaceutical company focusing on novel oral therapeutics for autoimmune diseases. The acquisition aims to advance Landos' lead asset, NX-13, a first-in-class oral NLRX1 agonist, for ulcerative colitis and Crohn's disease. "Acquiring Landos allows us to advance NX-13, a promising oral asset with potential to impact patients with ulcerative colitis and Crohn's disease," said Dr. Roopal Thakkar Roopal Thakkar, Senior Vice President and Chief Medical Officer at AbbVie. Gregory Oakes Gregory Oakes, President and CEO of Landos, highlighted NX-13's potential and Landos' commitment to addressing therapeutic gaps. NX-13 targets NLRX1, regulating immunometabolism and inflammation, key mechanisms in inflammatory bowel disease (IBD) pathogenesis. The Phase 2 NEXUS trial is currently enrolling patients. Under the agreement, AbbVie will acquire Landos for $20.42 per share in cash upon closing, with additional contingent value rights subject to a clinical development milestone. The transaction is expected to close in the second quarter of 2024. #AutoimmuneDiseases #AutoimmuneDiseases #PharmaAcquisition #TherapeuticAdvancement #NEXUStrial #MedicalBreakthrough #Agreement

Amicus Secures $430M Financing Deal with Blackstone After Pompe Disease Drug Approval Amicus Therapeutics has secured a significant $430 million financing deal with Blackstone Life Sciences and Blackstone Credit following FDA approval for its Pompe disease combination treatment. The deal includes a $400 million loan to refinance existing debt and a $30 million strategic investment in Amicus' common stock by Blackstone. With plans to launch the treatment in the US, Amicus aims to tap into the Pompe disease market, estimated to reach $1.8 billion by 2027. The company envisions peak sales of its combination therapy at $1.2 billion. What's next for Amicus in its pursuit of profitability? If you want to stay informed about the latest developments in the pharmaceutical industry, visit Pharmtales. They provide up-to-date coverage of the Latest Pharma News. #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #amicustherapeutics #blackstone #collaboration #pompedisease #opfolda #pombiliti #pharmaceuticalcompanies https://lnkd.in/dxnDeYtV

Primary Hyperoxaluria Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharma: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Primary Hyperoxaluria pipeline constitutes 8+ key companies continuously working towards developing 8+ Primary Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

🔥 Richardson Round Up 🔥 There has been some huge news in the market this week, check my previous post to see what else has happened..... some huge collaborations and investments! Let's round up the rest of the news. 💲 Pfizer have completed the acquisition of Seagen, this now means that Pfizer’s oncology portfolio includes over 25 approved medicines and biosimilars across more than 40 indications. 💲 Alkermes to Sell Mfg. Facility in Ireland to Novo Nordisk. They plan to enter into subcontracting arrangements to continue certain work currently performed at the facility for a period of time after closing of the transaction, which may continue through the end of 2025. 🤝 Charles River Laboratories have entered into an agreement with CELLphenomics GmbH,  The enhanced offering will provide Charles River clients with access to CELLphenomics’ 3D tumour model platform to further optimise oncological approaches for its clients. 🤝 Depixus has entered a collaboration with Daiichi Sankyo, Inc. to use their novel MAGNA technology to accelerate Daiichi's RNA-targeted drug discovery program. #cdmo #pharma #pharmaceutical #biosimilars #oncology

Arecor Therapeutics plc (AIM:AREC) CEO Sarah Howell speaks to Thomas Warner from Proactive after the #biopharmaceutical group announced the first commercial sale of a product that incorporates its proprietary #Arestat technology, known as #AT220. Part of a licence agreement with an unnamed global #pharma partner initiated in 2017, the milestone has triggered a payment to #Arecor. It will also receive royalties on sales. Howell explains the significance of the news, emphasising its importance for patients and the business. She says the achievement aligns with Arecor's vision of building a large, self-sustaining #biopharma company focused on improving patient care. While the partner involved in this achievement remains undisclosed, Howell shed light on Arecor's appeal to pharmaceutical collaborators and says the Arestat technology enables the company to enhance biosimilar products, providing more benefits to patients and giving partners a competitive edge in a high-value market. She says the financial impact is significant, with the milestone triggering licensed payments and initiating recurring royalty streams for #ArecorTherapeutics. As the year approaches its end, Howell hints at potential updates. The partnered portfolio shows promising progress, with recent announcements of licensed milestones and positive developments in clinical studies. Ongoing partnerships with pharma and #biotech companies are expected to expand, contributing to Arecor's growth. The company is actively developing its proprietary products, focusing on specialty hospital medications and #diabetes treatments. One of their lead diabetes products, #AT278, targets patients with high #insulin needs, presenting a disruptive solution in a growing market segment. Results from the clinical study are anticipated in Q1 2024. Watch at #Proactive #ProactiveInvestors #AIM #AREC https://ow.ly/kCmj50Q8Lny

Top BioPharma News: - Despite missing the primary endpoint in a key Duchenne muscular dystrophy (DMD) study, Sarepta is seeking broader FDA approval for Elevidys. This highlights the unmet need in DMD and Sarepta's commitment to advancing new treatments. - Roche's TIGIT program is delivering positive results, validating this emerging I-O target. Novartis’ Chinook deal is also gaining steam as their BION-1301 asset hits Phase 3 goals, reinforcing this pathway’s potential. Deciphera’s QINLOCK shows promise in GI tumors. - Sarepta’s Exondys 51 confirmatory study failure complicates future regulatory filing plans for this DMD drug. Pfizer’s facility closures in NJ and NC reflect ongoing industry consolidation and cost control efforts. Biden’s AI order brings regulatory changes that could impact FDA approvals. - Lexeo, MapLight Therapeutics, ManaT Bio, Rampart Bioscience, and Aiolos Bio collectively raised over $800M in recent financing rounds, highlighting continued robust biotech investment. - Merck KGaA is expanding its oncology pipeline via a $169M upfront deal for Hengrui Medicine’s PARP inhibitor. Novo Nordisk is boosting marketing capabilities with a $245M acquisition. - Detailed human brain maps are enabling new therapeutic insights. However, first-gen AI-designed drugs have underwhelmed clinically so far. - Roche’s expanded Vabysmo label threatens Regeneron’s Eylea franchise. Abbott is focusing on Skyrizi and Rinvoq as Humira sales decline due to biosimilar competition. - Santhera’s DMD drug Vamorolone gained FDA approval after a long development journey. Sanofi is evolving clinical plans for recently acquired Denali, Principia, and Kymab assets.

Latest Developments in Myelofibrosis Treatment Pipeline 2023: Regulatory Approvals from FDA, EMA, and PMDA, New Drug Innovations, Clinical Trials, Therapeutics, and Growth Prospects by DelveInsight #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Ready to advance your organization's role in shaping the future of pharma? Stop by Booth 23 at NEXT Pharma Summit from tomorrow!👋 Capptoo AG, along with Screver AG and Oncology Compass, are bringing groundbreaking innovations to Booth 23. Here's why you don't want to miss it: 👉 Witness the Cutting Edge: Discover how our solutions are revolutionizing the pharmaceutical industry. 👉Endless Possibilities: Explore how our advancements can unlock new frontiers in healthcare. 👉Expert Insights: Chat with our pharma specialists about the latest trends and find solutions for your specific needs. 👉Unleash the Potential: Dive deep into new opportunities and explore how we can collaborate to create a healthier future. Don't just take our word for it! Stop by Booth 23 and see the future of pharma in action. 🚀 #capptoo #screver #nextpharmasummit #oncologycompass

Milestone！BeiGene's Zanubrutinib becomes the first-ever blockbuster drug made by a pharma/biotech in China! BeiGene reported a total revenue of $634 million in the fourth quarter of 2023, a 67% increase year-over-year; the annual total revenue reached $2.5 billion, up 74% from the previous year. Zanubrutinib's global sales in the fourth quarter of 2023 reached $413 million, a 135% increase year-over-year; the annual global sales amounted to $1.3 billion, marking a 129% increase. In both the fourth quarter and the full year of 2023, both GAAP and adjusted R&D expenses increased year-over-year, primarily due to investments in new technology platforms and drug modalities, advancing preclinical projects into clinical stages and early clinical projects into later stages of development. During the fourth quarter and the full year of 2023, the prepayments for R&D of licensed-in candidate drugs in progress were $31.8 million and $46.8 million, respectively, compared to $48.7 million and $68.7 million in the same periods of the previous year. Highlights of the 2024 milestone events include: - Zanubrutinib is expected to receive U.S. FDA approval for use in combination with obinutuzumab for the treatment of R/R FL, becoming the BTK inhibitor with the widest range of approved indications in its class. - Tislelizumab is anticipated to gain U.S. FDA approval for the first-line and second-line treatment of ESCC, further expanding the company's global layout of innovative product portfolios in solid tumors. For more news, please visit https://lnkd.in/gzJYFY2i. #BeiGene #Zanubrutinib #blockbusterdrug #drugdiscovery #drugdevelopment #Chinabiotechnews #DrugTimes #WorldBDDay